247  Total SME IPOs listed in 2024

9572.65 Crs.  Total funds raised in 2024

223  SME IPOs listed with Gain in 2024

24  SME IPOs listed with loss in 2024

247  Total SME IPOs listed in 2024

9572.65 Crs.  Total funds raised in 2024

223  SME IPOs listed with Gain in 2024

24  SME IPOs listed with loss in 2024

247  Total SME IPOs listed in 2024

9572.65 Crs.  Total funds raised in 2024

223  SME IPOs listed with Gain in 2024

24  SME IPOs listed with loss in 2024

247  Total SME IPOs listed in 2024

9572.65 Crs.  Total funds raised in 2024

223  SME IPOs listed with Gain in 2024

24  SME IPOs listed with loss in 2024

Windlas Biotech Limited IPO (Windlas Biotech IPO) Details

Windlas Biotech Limited is an Pharmaceutical based company, located in Dehradun, Windlas Biotech Limited IPO size was 401.54 Cr. and was issued at 460.00 per share. The share of Windlas Biotech Limited were listed at 406.70 per share and are currently trading at 1012.60 per share.

Type :
Sub Sector : Domestic Pharmaceutical Formulations Contract Development And Manufacturing
MainBoard IPO

Financial Summary (at the time of ipo, on annualised basis)

Revenue :
430.70 Cr.

PAT :
15.57 Cr.

Pricing Report

Issue Price :
460.00

Listing Price :
406.70

Current Market Price :
1012.60

Issue Price vs CMP :
552.6 (120.13%)

listing Price vs CMP :
605.9 (148.98%)

Performance Report (CAGR* wise)

CAGR : 25.82
-ve 0 6 9 12+
Above Average

*CAGR is calculated basis issue price at the time of IPO and Current Market Price without taking into Consideration Bonus/Right issue.

About Windlas Biotech

Company Information
Windlas Biotech Limited is among the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue (Source: CRISIL Report). With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms, along with significant expertise in providing specialized capabilities, including high potency, controlled substances, and low-solubility products, they offer a comprehensive range of CDMO services. These services include product discovery, product development, licensing, and commercial manufacturing of generic products, including complex generics, all in compliance with current Good Manufacturing Practices (GMP), with a focus on improving safety, efficacy, and cost. In Fiscal 2020, their market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry (Source: CRISIL
Show More
Object of Issue
  • To purchase equipment required for capacity expansion of their existing facility at Dehradun Plant IV
  • To finance incremental working capital requirements of the company
  • Repayment/prepayment of company's borrowings
  • General Corporate Purposes

Windlas Biotech MainBoard IPO Details (at the time of IPO)

IPO Type :
Book Building
IPO Date :
Aug, 2021
IPO Size :
401.54 Cr.
IPO Subscription :
22.44 X     
PE Multiple :
64.00
Merchant Banker :
Dam Capital Advisors Limited (Formerly Idfc Securities Limited)
IPO Registrar:
Link Intime India Private Limited

Thinking of
Listing Your Business through
SME IPO?

We can Help!

Contact Us Today

See Other MainBoard IPOs in Dehradun

Peer Companies Of This Sector

FAQs

Windlas Biotech operates in Pharmaceutical and Domestic Pharmaceutical Formulations Contract Development And Manufacturing. The Issue is listed on MainBoard in Aug, 2021. Windlas Biotech IPO size was 401.54 Cr. with Issue price of 460.00 .

Merchant Banker(s) of Windlas Biotech IPO: Dam Capital Advisors Limited (Formerly Idfc Securities Limited) , Iifl Securities Limited , SBI Capital Markets Limited

Windlas Biotech IPO subscription was 22.44 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.

Windlas Biotech IPO listed at a listing price of 406.70 against the offer price of 460.00.

The current market price of Windlas Biotech is 1012.60.

Services

IPO Advisory
IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Readiness
IPO Readiness
IPO Roadmap by improving Business Efficiencies, Financial Parameters and Corporate Structure to become IPO ready.
Fund Raising
Fund Raising
Fuelling a company's growth through Pre IPO Fund Raise, Private Equity, and Angel Investing.
SME : Business Scaling
SME Business Upscaling
Provide support to build a scalable SME business by unleashing the SME potential.
Post IPO Montoring
Post IPO Mentoring
Assisting with post IPO regulatory requirements and Performance Monitoring to achieve the milestone of Mainboard migration.

Thinking of
Listing Your Business through SME IPO?

We can help! Contact Us

Why Us?

  • Leading portal for IPOs
  • End to End Solutions
  • Known for Transparency